In launching its hostile takeover attempt for Warner-Lambert, its most important partner, in order to get 100% of the revenues of Lipitor, Pfizer underlined its own immense growth challenge, and that of the industry at large. Indeed, the growth problem is so serious that Pfizer is reversing what had seemed a highly successful alternative strategy to M&A--it's late-stage co-promotions. Meanwhile, in signing its own deal with American Home, Warner was sending a similar message: its admission of the difficulty of ever finding, through internal research or alliances, a product important enough to replace the earnings of Lipitor.
by Roger Longman
In December 1987, a shoe dropped in the halls of the pharmaceutical industry. Roche 's attempt to take over Sterling Drug did more than introduce to drug companies a...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.
